HitGen to acquire fragment and structure-based biotech company Vernalis
This article was originally published here
The acquisition is for the entire issued share capital of Vernalis (R&D) Limited, for $25M in cash. The closing of this transaction is subject to customary conditions and
The post HitGen to acquire fragment and structure-based biotech company Vernalis appeared first on Pharmaceutical Business review.
Leave a Reply
Want to join the discussion?Feel free to contribute!